全文获取类型
收费全文 | 4410篇 |
免费 | 261篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 78篇 |
妇产科学 | 56篇 |
基础医学 | 426篇 |
口腔科学 | 196篇 |
临床医学 | 429篇 |
内科学 | 1694篇 |
皮肤病学 | 20篇 |
神经病学 | 196篇 |
特种医学 | 244篇 |
外科学 | 441篇 |
综合类 | 99篇 |
一般理论 | 2篇 |
预防医学 | 377篇 |
眼科学 | 114篇 |
药学 | 155篇 |
中国医学 | 4篇 |
肿瘤学 | 142篇 |
出版年
2023年 | 22篇 |
2022年 | 20篇 |
2021年 | 71篇 |
2020年 | 31篇 |
2019年 | 74篇 |
2018年 | 119篇 |
2017年 | 54篇 |
2016年 | 62篇 |
2015年 | 86篇 |
2014年 | 143篇 |
2013年 | 190篇 |
2012年 | 281篇 |
2011年 | 306篇 |
2010年 | 206篇 |
2009年 | 160篇 |
2008年 | 269篇 |
2007年 | 319篇 |
2006年 | 238篇 |
2005年 | 253篇 |
2004年 | 240篇 |
2003年 | 219篇 |
2002年 | 193篇 |
2001年 | 62篇 |
2000年 | 54篇 |
1999年 | 44篇 |
1998年 | 78篇 |
1997年 | 63篇 |
1996年 | 35篇 |
1995年 | 26篇 |
1994年 | 35篇 |
1993年 | 42篇 |
1992年 | 39篇 |
1991年 | 38篇 |
1990年 | 43篇 |
1989年 | 34篇 |
1988年 | 44篇 |
1987年 | 36篇 |
1986年 | 36篇 |
1985年 | 42篇 |
1984年 | 26篇 |
1983年 | 22篇 |
1982年 | 32篇 |
1981年 | 19篇 |
1980年 | 24篇 |
1978年 | 27篇 |
1977年 | 24篇 |
1975年 | 18篇 |
1973年 | 19篇 |
1969年 | 18篇 |
1968年 | 18篇 |
排序方式: 共有4695条查询结果,搜索用时 0 毫秒
101.
Calcium channel blocker toxicity can be devastating. Initial therapy with fluid, calcium, and adrenoreceptor agonists should be prompt and novel therapies can be added if no response. Determining cardiogenic shock versus vasoplegia with echocardiogram or other hemodynamic monitoring may guide treatment options. 相似文献
102.
103.
104.
105.
106.
107.
108.
109.
110.
Joshi PH Chaudhari S Blaha MJ Jones SR Martin SS Post WS Cannon CP Fonarow GC Wong ND Amsterdam E Hirshfeld JW Blumenthal RS 《Clinical cardiology》2012,35(7):404-409
Recently, a debate over the merits of statin therapy in primary prevention was published in the Wall Street Journal. The statin opponent claimed that statins should only be used in secondary prevention and never in any primary-prevention patients at risk for cardiovascular events. In this evidence-based rebuttal to those claims, we review the evidence supporting the efficacy of statin therapy in primary prevention. Cardiovascular risk is a continuum in which those at an elevated risk of events stand to benefit from early initiation of therapy. Statins should not be reserved until after a patient suffers the catastrophic consequences of atherosclerosis. Contrary to the assertions of the statin opponent, this principle has been demonstrated through reductions in heart attacks, strokes, and mortality in numerous randomized controlled primary-prevention statin trials. Furthermore, data show that once a patient tolerates the initial treatment period, the few side effects that subsequently emerge are largely reversible. Accordingly, every major guidelines committee endorses statin use in secondary prevention and selectively in primary prevention for those with risk factors. The foundation for prevention remains increased physical activity, better dietary habits, and smoking cessation. However, prevention of heart attacks, strokes, and death from cardiovascular disease does not have to be all or none-all statin or all lifestyle. In selected at-risk individuals, the combination of pharmacotherapy and lifestyle changes is more effective than either alone. Future investigation in prevention should focus on improving our ability to identify these at-risk individuals. 相似文献